NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-AG-21-052 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-038 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-22-034 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices are not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.
Funding Opportunity RFA-NS-22-033 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for Phase II SBIR applications to test promising cerebrovascular interventions in the NINDS Stroke Preclinical Assessment Network (SPAN). SPAN will facilitate the testing of up to 8 promising cerebroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic stroke (e.g., transient middle cerebral artery occlusion (tMCAo)). The PIs of the awarded interventions will become part of the network and will collaborate with the SPAN Coordinating Center (RFA-NS-22-004), testing laboratories (RFA-NS-22-003), and other intervention contributors (RFA-NS-22-032) to facilitate the parallel testing of multiple cerebroprotective interventions in experimental models of ischemic stroke. Applicants must propose a research project involving a promising cerebroprotective intervention, supported by rigorous and extensive preliminary data, to be tested in SPAN. If successful, this network will accelerate the identification of the most promising cerebroprotective therapies for future pivotal clinical trials and span the gap between small businesses, preclinical testing laboratories, and a pipeline to clinical testing, in a cost-and time-effective fashion.
Funding Opportunity RFA-NS-22-032 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for research projects to test promising cerebrovascular interventions in the NINDS Stroke Preclinical Assessment Network (SPAN). SPAN will facilitate the testing of up to 8 promising cerebroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic stroke (e.g., transient middle cerebral artery occlusion, tMCAo). The PIs of the awarded interventions will become part of the network and will collaborate with the SPAN Coordinating Center (RFA-NS-22-004), testing laboratories (RFA-NS-22-003), and other intervention contributors (RFA-NS-22-032, RFA-NS-22-033) to facilitate the parallel testing of multiple cerebroprotective interventions in experimental models of ischemic stroke. Applicants must propose a promising cerebroprotective intervention, supported by rigorous and extensive preliminary data, to be tested in SPAN. If successful, this network will accelerate the identification of the most promising cerebroprotective therapies for future pivotal clinical trials and span the gap between small businesses, preclinical testing laboratories, and a pipeline to clinical testing, in a cost-and time-effective fashion.
Funding Opportunity RFA-NS-22-003 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for testing laboratories to take part in the NINDS Stroke Preclinical Assessment Network (SPAN). SPAN will facilitate the testing of up to 8 promising cerebroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic stroke (e.g., transient middle cerebral artery occlusion (tMCAO)). Awarded testing laboratories will compose the main infrastructure of the network and will be expected to work with the SPAN Coordinating Center and intervention contributors to facilitate the parallel testing of multiple cerebroprotective interventions in experimental models of ischemic stroke. If successful, this network will accelerate the identification of the most promising neuroprotective therapies for future pivotal clinical trials and span the gap between preclinical and clinical testing, in a cost-and time-effective fashion
Funding Opportunity RFA-NS-22-004 from the NIH Guide for Grants and Contracts. Recent advances in endovascular thrombectomy offer a new opportunity to reconsider neuroprotective agents as adjunctive therapies to extend the time window for reperfusion and to improve long-term functional outcome. The purpose of this funding opportunity announcement (FOA) issued by NINDS is to invite applications for the Coordinating Center (CC) for the NIH Stroke Preclinical Assessment Network (SPAN). SPAN will facilitate testing of up to 6 promising neuroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic stroke (e.g., transient middle cerebral artery occlusion). The CC will work with the awarded network sites (RFA-NS-18-033) and will provide centralized administrative oversight and coordination of all aspects of the network. If successful, this network will accelerate the identification of the most promising neuroprotective therapies for future pivotal clinical trials and span the gap between preclinical and clinical testing, in a cost-and time-effective fashion.
Notice NOT-DK-22-008 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-047 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-048 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-049 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-050 from the NIH Guide for Grants and Contracts
Notice NOT-HG-22-011 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-045 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-046 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-044 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-041 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-042 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-23-006 from the NIH Guide for Grants and Contracts. The National Institute on Aging seeks applications for the Coordinating Center (CC) of the Claude D. Pepper Older Americans Independence Centers (OAIC) program. The CC serves as a facilitator for OAIC site interactions and as a conduit for translating OAIC objectives and findings to both scientific and general audiences. The proposed CC must demonstrate an ability to work cooperatively with all OAIC sites and possess sufficient scientific expertise in geriatrics and related areas to serve the national coordination functions of the OAIC program. The CC should be proposed only by institutions with (1) the ability to coordinate multi-site projects as demonstrated by previous HHS funding for a coordinating center of a multi-site research grant, and (2) demonstrated scientific expertise in clinical aging research.
Notice NOT-DA-22-001 from the NIH Guide for Grants and Contracts